TY - JOUR
T1 - PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation
AU - Lind-Holm Mogensen, Frida
AU - Sousa, Carole
AU - Ameli, Corrado
AU - Badanjak, Katja
AU - Pereira, Sandro L.
AU - Muller, Arnaud
AU - Kaoma, Tony
AU - Coowar, Djalil
AU - Scafidi, Andrea
AU - Poovathingal, Suresh K.
AU - Tziortziou, Maria
AU - Antony, Paul M.A.
AU - Nicot, Nathalie
AU - Ginolhac, Aurélien
AU - Vogt Weisenhorn, Daniela M.
AU - Wurst, Wolfgang
AU - Poli, Aurélie
AU - Nazarov, Petr V.
AU - Skupin, Alexander
AU - Grünewald, Anne
AU - Michelucci, Alessandro
N1 - Funding
F.L-HM. was supported by the Luxembourg National Research Fund (FNR) through the FNR-PRIDE program i2TRON for doctoral education (PRIDE/14254520/I2TRON). C.S. was supported by the FNR (AFR/6916713) and the Fondation du Pélican de Mie et Pierre Hippert-Faber under the aegis of Fondation de Luxembourg. C.A. and K.B. were supported by the FNR-PRIDE program CriTiCS for doctoral education (PRIDE/10907093/CriTiCS). In addition, C.A. was supported by the CMCM (Caisse Médico-Complémentaire Mutualiste Luxembourg) matching grant. MT received funding from the FNR as part of the FNR-PRIDE program NextImmune2 for doctoral education (PRIDE21/16749720). W.W. was supported by the Deutsche Zentrum für Psychische Gesundheit (DZPG), site Munich-Augsburg. PVN was supported by a FNR CORE grant (C21/BM/15739125/DIOMEDES). Al.S. was supported by the FNR through an INTER grant (INTER/DFG/17/11583046). AG was supported by the FNR within the framework of the ATTRACT (Model-IPD, FNR9631103) program as well as the National Centre of Excellence in Research on Parkinson’s disease (NCER-PD, FNR/NCER13/BM/11264123). In addition, AG and SLP received funding from the FNR within the framework of a CORE grant (“CAMeSyn”, C19/BM/13688526). Lastly, we acknowledge financial support from the Action LIONS « Vaincre le Cancer» Luxembourg. For the purpose of open access, and in fulfilment of the obligations arising from the FNR grant agreement, the author has applied a Creative Commons Attribution 4.0 International (CC BY 4.0) license to any Author Accepted Manuscript version arising from this submission.
Publisher Copyright:
© The Author(s) 2024.
PY - 2024/7/16
Y1 - 2024/7/16
N2 - Background: Specific microglia responses are thought to contribute to the development and progression of neurodegenerative diseases, including Parkinson’s disease (PD). However, the phenotypic acquisition of microglial cells and their role during the underlying neuroinflammatory processes remain largely elusive. Here, according to the multiple-hit hypothesis, which stipulates that PD etiology is determined by a combination of genetics and various environmental risk factors, we investigate microglial transcriptional programs and morphological adaptations under PARK7/DJ-1 deficiency, a genetic cause of PD, during lipopolysaccharide (LPS)-induced inflammation. Methods: Using a combination of single-cell RNA-sequencing, bulk RNA-sequencing, multicolor flow cytometry and immunofluorescence analyses, we comprehensively compared microglial cell phenotypic characteristics in PARK7/DJ-1 knock-out (KO) with wildtype littermate mice following 6- or 24-h intraperitoneal injection with LPS. For translational perspectives, we conducted corresponding analyses in human PARK7/DJ-1 mutant induced pluripotent stem cell (iPSC)-derived microglia and murine bone marrow-derived macrophages (BMDMs). Results: By excluding the contribution of other immune brain resident and peripheral cells, we show that microglia acutely isolated from PARK7/DJ-1 KO mice display a distinct phenotype, specially related to type II interferon and DNA damage response signaling, when compared with wildtype microglia, in response to LPS. We also detected discrete signatures in human PARK7/DJ-1 mutant iPSC-derived microglia and BMDMs from PARK7/DJ-1 KO mice. These specific transcriptional signatures were reflected at the morphological level, with microglia in LPS-treated PARK7/DJ-1 KO mice showing a less amoeboid cell shape compared to wildtype mice, both at 6 and 24 h after acute inflammation, as also observed in BMDMs. Conclusions: Taken together, our results show that, under inflammatory conditions, PARK7/DJ-1 deficiency skews microglia towards a distinct phenotype characterized by downregulation of genes involved in type II interferon signaling and a less prominent amoeboid morphology compared to wildtype microglia. These findings suggest that the underlying oxidative stress associated with the lack of PARK7/DJ-1 affects microglia neuroinflammatory responses, which may play a causative role in PD onset and progression.
AB - Background: Specific microglia responses are thought to contribute to the development and progression of neurodegenerative diseases, including Parkinson’s disease (PD). However, the phenotypic acquisition of microglial cells and their role during the underlying neuroinflammatory processes remain largely elusive. Here, according to the multiple-hit hypothesis, which stipulates that PD etiology is determined by a combination of genetics and various environmental risk factors, we investigate microglial transcriptional programs and morphological adaptations under PARK7/DJ-1 deficiency, a genetic cause of PD, during lipopolysaccharide (LPS)-induced inflammation. Methods: Using a combination of single-cell RNA-sequencing, bulk RNA-sequencing, multicolor flow cytometry and immunofluorescence analyses, we comprehensively compared microglial cell phenotypic characteristics in PARK7/DJ-1 knock-out (KO) with wildtype littermate mice following 6- or 24-h intraperitoneal injection with LPS. For translational perspectives, we conducted corresponding analyses in human PARK7/DJ-1 mutant induced pluripotent stem cell (iPSC)-derived microglia and murine bone marrow-derived macrophages (BMDMs). Results: By excluding the contribution of other immune brain resident and peripheral cells, we show that microglia acutely isolated from PARK7/DJ-1 KO mice display a distinct phenotype, specially related to type II interferon and DNA damage response signaling, when compared with wildtype microglia, in response to LPS. We also detected discrete signatures in human PARK7/DJ-1 mutant iPSC-derived microglia and BMDMs from PARK7/DJ-1 KO mice. These specific transcriptional signatures were reflected at the morphological level, with microglia in LPS-treated PARK7/DJ-1 KO mice showing a less amoeboid cell shape compared to wildtype mice, both at 6 and 24 h after acute inflammation, as also observed in BMDMs. Conclusions: Taken together, our results show that, under inflammatory conditions, PARK7/DJ-1 deficiency skews microglia towards a distinct phenotype characterized by downregulation of genes involved in type II interferon signaling and a less prominent amoeboid morphology compared to wildtype microglia. These findings suggest that the underlying oxidative stress associated with the lack of PARK7/DJ-1 affects microglia neuroinflammatory responses, which may play a causative role in PD onset and progression.
KW - Lipopolysaccharide
KW - Microglia
KW - Microglia morphology
KW - Neuroinflammation
KW - PARK7/DJ-1
KW - Parkinson’s disease
UR - http://www.scopus.com/inward/record.url?scp=85198753594&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/39014482/
U2 - 10.1186/s12974-024-03164-x
DO - 10.1186/s12974-024-03164-x
M3 - Article
C2 - 39014482
AN - SCOPUS:85198753594
SN - 1742-2094
VL - 21
JO - Journal of Neuroinflammation
JF - Journal of Neuroinflammation
IS - 1
M1 - 174
ER -